Phibro Animal Health Corporation (PAHC)
USD 19.48
(4.73%)
USD 19.48
(4.73%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 312.48 Million USD | 4.98% |
| 2023 | 298.23 Million USD | 4.5% |
| 2022 | 285.4 Million USD | 5.16% |
| 2021 | 271.4 Million USD | 5.64% |
| 2020 | 256.9 Million USD | -2.91% |
| 2019 | 264.6 Million USD | -0.86% |
| 2018 | 266.9 Million USD | 7.49% |
| 2017 | 248.3 Million USD | 3.89% |
| 2016 | 239 Million USD | 1.11% |
| 2015 | 236.37 Million USD | 13.75% |
| 2014 | 207.8 Million USD | 16.11% |
| 2013 | 178.96 Million USD | 9.03% |
| 2012 | 164.13 Million USD | 11.91% |
| 2011 | 146.66 Million USD | -5.19% |
| 2010 | 154.7 Million USD | 19.37% |
| 2009 | 129.6 Million USD | 6.49% |
| 2008 | 121.7 Million USD | 9.44% |
| 2007 | 111.2 Million USD | 22.06% |
| 2006 | 91.1 Million USD | 27.77% |
| 2005 | 71.3 Million USD | -20.07% |
| 2004 | 89.2 Million USD | 0.0% |
| 2003 | 89.2 Million USD | 9.72% |
| 2002 | 81.3 Million USD | 17.15% |
| 2001 | 69.4 Million USD | -5.45% |
| 2000 | 73.4 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 78.87 Million USD | 0.33% |
| 2024 Q4 | 86.77 Million USD | 10.02% |
| 2024 Q2 | 78.61 Million USD | 16.12% |
| 2024 FY | 312.48 Million USD | 4.78% |
| 2024 Q1 | 67.7 Million USD | -11.69% |
| 2023 Q2 | 77.38 Million USD | 12.73% |
| 2023 Q4 | 76.66 Million USD | 1.41% |
| 2023 Q3 | 75.6 Million USD | -2.31% |
| 2023 FY | 298.23 Million USD | 4.5% |
| 2023 Q1 | 68.64 Million USD | -12.55% |
| 2022 Q2 | 70.67 Million USD | 9.27% |
| 2022 FY | 285.4 Million USD | 5.16% |
| 2022 Q4 | 78.5 Million USD | 9.6% |
| 2022 Q3 | 71.62 Million USD | 1.35% |
| 2022 Q1 | 64.67 Million USD | -7.34% |
| 2021 Q3 | 69.16 Million USD | 1.32% |
| 2021 Q4 | 69.8 Million USD | 0.92% |
| 2021 Q2 | 68.26 Million USD | 6.47% |
| 2021 Q1 | 64.11 Million USD | 5.81% |
| 2021 FY | 271.4 Million USD | 5.64% |
| 2020 Q4 | 60.6 Million USD | -12.87% |
| 2020 FY | 256.9 Million USD | -2.91% |
| 2020 Q1 | 57.66 Million USD | -11.7% |
| 2020 Q2 | 69.1 Million USD | 19.84% |
| 2020 Q3 | 69.55 Million USD | 0.65% |
| 2019 FY | 264.6 Million USD | -0.86% |
| 2019 Q2 | 68.64 Million USD | 4.31% |
| 2019 Q3 | 64.87 Million USD | -5.5% |
| 2019 Q4 | 65.3 Million USD | 0.66% |
| 2019 Q1 | 65.8 Million USD | -2.51% |
| 2018 Q2 | 66.91 Million USD | 5.58% |
| 2018 Q1 | 63.38 Million USD | 0.45% |
| 2018 FY | 266.9 Million USD | 7.49% |
| 2018 Q4 | 67.5 Million USD | -2.27% |
| 2018 Q3 | 69.06 Million USD | 3.21% |
| 2017 Q3 | 60.62 Million USD | -4.53% |
| 2017 Q1 | 60.99 Million USD | 2.35% |
| 2017 FY | 248.3 Million USD | 3.89% |
| 2017 Q4 | 63.1 Million USD | 4.09% |
| 2017 Q2 | 63.49 Million USD | 4.1% |
| 2016 FY | 239 Million USD | 1.11% |
| 2016 Q4 | 59.6 Million USD | -0.59% |
| 2016 Q3 | 59.95 Million USD | -3.94% |
| 2016 Q2 | 62.41 Million USD | 3.75% |
| 2016 Q1 | 60.16 Million USD | -1.13% |
| 2015 Q3 | 59.11 Million USD | 5.39% |
| 2015 FY | 236.37 Million USD | 13.75% |
| 2015 Q2 | 56.08 Million USD | -7.03% |
| 2015 Q4 | 60.84 Million USD | 2.94% |
| 2015 Q1 | 60.32 Million USD | 11.1% |
| 2014 Q2 | 51.15 Million USD | 3.32% |
| 2014 Q4 | 54.3 Million USD | 2.76% |
| 2014 Q1 | 49.51 Million USD | 2.82% |
| 2014 Q3 | 52.84 Million USD | 3.3% |
| 2014 FY | 207.8 Million USD | 16.11% |
| 2013 Q3 | 45.75 Million USD | 5.95% |
| 2013 Q2 | 43.18 Million USD | 1.55% |
| 2013 Q4 | 48.15 Million USD | 5.25% |
| 2013 Q1 | 42.52 Million USD | 0.0% |
| 2013 FY | 178.96 Million USD | 9.03% |
| 2012 FY | 164.13 Million USD | 11.91% |
| 2011 FY | 146.66 Million USD | -5.19% |
| 2010 Q2 | 40.5 Million USD | 12.19% |
| 2010 Q1 | 36.1 Million USD | -7.2% |
| 2010 FY | 154.7 Million USD | 19.37% |
| 2009 Q4 | 38.9 Million USD | 33.68% |
| 2009 Q3 | 29.1 Million USD | -3.96% |
| 2009 Q2 | 30.3 Million USD | -0.98% |
| 2009 FY | 129.6 Million USD | 6.49% |
| 2009 Q1 | 30.6 Million USD | -10.79% |
| 2008 Q4 | 34.3 Million USD | 12.83% |
| 2008 Q2 | 29.1 Million USD | 3.93% |
| 2008 Q1 | 28 Million USD | -6.04% |
| 2008 FY | 121.7 Million USD | 9.44% |
| 2008 Q3 | 30.4 Million USD | 4.47% |
| 2007 FY | 111.2 Million USD | 22.06% |
| 2007 Q4 | 29.8 Million USD | 13.31% |
| 2007 Q2 | 30.7 Million USD | 26.34% |
| 2007 Q1 | 24.3 Million USD | -10.99% |
| 2007 Q3 | 26.3 Million USD | -14.33% |
| 2006 Q2 | 20.2 Million USD | 5.21% |
| 2006 Q3 | 24.5 Million USD | 21.29% |
| 2006 Q4 | 27.3 Million USD | 11.43% |
| 2006 FY | 91.1 Million USD | 27.77% |
| 2006 Q1 | 19.2 Million USD | 14.29% |
| 2005 Q2 | 13.5 Million USD | -39.19% |
| 2005 FY | 71.3 Million USD | -20.07% |
| 2005 Q4 | 16.8 Million USD | -10.64% |
| 2005 Q1 | 22.2 Million USD | -4.31% |
| 2005 Q3 | 18.8 Million USD | 39.26% |
| 2004 Q3 | 22.8 Million USD | 3.17% |
| 2004 FY | 89.2 Million USD | 0.0% |
| 2004 Q1 | 21.2 Million USD | 7.07% |
| 2004 Q2 | 22.1 Million USD | 4.25% |
| 2004 Q4 | 23.2 Million USD | 1.75% |
| 2003 Q1 | 22.2 Million USD | 0.0% |
| 2003 Q3 | 23.3 Million USD | -2.92% |
| 2003 Q4 | 19.8 Million USD | -15.02% |
| 2003 FY | 89.2 Million USD | 9.72% |
| 2003 Q2 | 24 Million USD | 8.11% |
| 2002 FY | 81.3 Million USD | 17.15% |
| 2001 FY | 69.4 Million USD | -5.45% |
| 2000 FY | 73.4 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | 73.06 Million USD | -327.672% |
| Theratechnologies Inc. | 62.12 Million USD | -402.965% |
| Safety Shot Inc | -74.45 Thousand USD | 419787.874% |
| Cosmos Health Inc. | 4.34 Million USD | -7084.321% |
| Cronos Group Inc. | 6.99 Million USD | -4369.913% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 29.167% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 103231.023% |
| Organogenesis Holdings Inc. | 309.79 Million USD | -0.871% |
| Universe Pharmaceuticals INC | 10.07 Million USD | -3000.722% |
| ProPhase Labs, Inc. | 16.23 Million USD | -1824.3% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | -6485.606% |
| Dynavax Technologies Corporation | 182.11 Million USD | -71.586% |
| Radius Health, Inc. | 307.71 Million USD | -1.552% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -56308.548% |
| Alvotech | -69.42 Million USD | 550.127% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -3647.219% |
| Alpha Teknova, Inc. | 10.29 Million USD | -2935.033% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | 27.434% |
| SCYNEXIS, Inc. | 124.51 Million USD | -150.959% |
| Harrow Health, Inc. | 90.55 Million USD | -245.087% |
| Biofrontera Inc. | 16.62 Million USD | -1779.395% |
| DURECT Corporation | 6.83 Million USD | -4474.543% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 40.336% |
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | -2.353% |
| OptiNose, Inc. | 62.35 Million USD | -401.15% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -10131.477% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | -950.306% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | -833.19% |
| SIGA Technologies, Inc. | 122.09 Million USD | -155.944% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | -646.683% |
| Shineco, Inc. | 882.16 Thousand USD | -35322.618% |
| Procaps Group S.A. | 239.56 Million USD | -30.437% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -23900.538% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 42011.485% |
| Viatris Inc. | 6.43 Billion USD | 95.147% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -3647.219% |
| Rockwell Medical, Inc. | 8.7 Million USD | -3490.154% |
| Incannex Healthcare Limited | 12 Thousand USD | -2603958.333% |
| Aytu BioPharma, Inc. | 54.58 Million USD | -472.467% |
| Tilray Brands, Inc. | 223.35 Million USD | -39.908% |
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | 4.195% |
| PetIQ, Inc. | 252.74 Million USD | -23.64% |
| Silver Spike Investment Corp. | 8.1 Million USD | -3756.627% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 83.085% |
| Journey Medical Corporation | 52.52 Million USD | -494.975% |
| Alimera Sciences, Inc. | 61.17 Million USD | -410.85% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -7355.845% |
| Assertio Holdings, Inc. | 125.04 Million USD | -149.892% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 4588075.334% |
| Embecta Corp. | 749.9 Million USD | 58.33% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 13065.319% |
| Procaps Group, S.A. | 239.56 Million USD | -30.437% |
| PainReform Ltd. | -15 Thousand USD | 2083346.667% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | -1052.366% |
| Hempacco Co., Inc. | -1.21 Million USD | 25801.474% |
| Talphera, Inc. | -4.89 Million USD | 6483.8% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 36.267% |
| Alvotech | -69.42 Million USD | 550.127% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 55.959% |
| Kamada Ltd. | 52.59 Million USD | -494.164% |
| Indivior PLC | 907 Million USD | 65.547% |
| Currenc Group, Inc. | 17.35 Million USD | -1700.424% |
| Evoke Pharma, Inc. | 4.97 Million USD | -6176.414% |
| Flora Growth Corp. | 17.73 Million USD | -1661.681% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 13065.319% |
| Evolus, Inc. | 140.52 Million USD | -122.37% |
| HUTCHMED (China) Limited | 453.55 Million USD | 31.102% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 9.152% |
| Akanda Corp. | 111.44 Thousand USD | -280285.647% |